<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004962</url>
  </required_header>
  <id_info>
    <org_study_id>35RC18_8857_SYNOFRESH</org_study_id>
    <nct_id>NCT04004962</nct_id>
  </id_info>
  <brief_title>Use of Infrared Spectroscopy in Fast Septic Arthritis Diagnosis</brief_title>
  <acronym>SYNOFRESH</acronym>
  <official_title>Use of Infrared Spectroscopy in Fast Septic Arthritis Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the diagnostic performance of infrared spectroscopy on fresh synovial fluids in
      early septic arthritis diagnosis in patients with acute joint effusion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis of a joint effusion is frequently a medical emergency, especially when septic
      arthritis is suspected. Septic arthritis diagnosis relies on microscopic and bacteriological
      analysis of synovial fluid obtained by arthrocentesis. Direct microscopic examination can be
      made within 2 to 12 hours but it is negative in about 50 % of the cases. It is necessary to
      wait 72 hours to obtain the result of the culture and reasonably rule out the diagnosis of
      septic arthritis. A method of establishing an immediate etiological diagnosis could improve
      the care of patients with joint effusion that is a therapeutic emergency and justify a
      hospitalization and a parenteral antibiotic therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of the cause of joint effusion</measure>
    <time_frame>Up to 7 days (time to perform Spectroscopy and collect laboratory results)</time_frame>
    <description>The final diagnosis of the cause of joint effusion is made by the clinician based on the clinical and laboratory data : septic arthritis or other causes of arthritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization</measure>
    <time_frame>Up to 2 months (time to collect data on hospitalization duration and antibiotic therapy duration)</time_frame>
    <description>The clinician will be asked to state how a positive or a negative result of the diagnostic test under study would have affected his decision to hospitalize the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of antibiotics</measure>
    <time_frame>Up to 2 months (time to collect data on hospitalization duration and antibiotic therapy duration)</time_frame>
    <description>The clinician will be asked to state how a positive or a negative result of the diagnostic test under study would have affected his decision to start antibiotic therapy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Joint Effusion</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infrared spectroscopy</intervention_name>
    <description>Infrared spectroscopy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients benefiting from joint fluid puncture for diagnostic purposes in the rheumatology
        hospitals participating in the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients over 18 year old

          -  patients with an acute arthritis defined by an evolution of less than 6 weeks

          -  patients benefiting from joint fluid puncture for diagnostic purposes in the
             rheumatology hospitals participating in the study

          -  patients who received information about the protocol and have not expressed opposition
             to participate

        Exclusion Criteria:

          -  patients opposing the study

          -  protected major (safeguard justice, trusteeship and guardianship) and persons deprived
             of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-David Albert, MD</last_name>
    <phone>02.99.26.71.40</phone>
    <email>jean-david.albert@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel HOPPE, MD</last_name>
      <phone>02.41.35.38.34</phone>
      <email>EmHoppe@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry MARHADOUR, MD</last_name>
      <phone>02.98.22.33.33</phone>
      <email>thierry.marhadour@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion COUDERC, MD</last_name>
      <phone>04.73.75.14.88</phone>
      <email>mcouderc@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit LE GOFF, MD, PhD</last_name>
      <phone>02.40.08.33.33</phone>
      <email>benoit.legoff@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-David Albert, MD</last_name>
      <phone>02.99.26.71.40</phone>
      <email>jean-david.albert@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe GOUPILLE, MD, PhD</last_name>
      <phone>02.18.37.05.89</phone>
      <email>philippe.goupille@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

